# Phase 2b: Orange Book & Purple Book Ingest Report

## Zusammenfassung

| Metrik | Wert |
|--------|------|
| Orange Book Products geladen | 47,588 |
| Purple Book Products geladen | 12 |
| Drugs mit Match (von 43) | 34 |
| Patente geladen | 17,150 |
| Exclusivity Records | 2,254 |
| LOE-Summary berechnet | 34 Drugs |

## Drug Matching

| Drug | Quelle | Appl_No | Trade Name | Match |
|------|--------|---------|------------|-------|
| acarbose | Orange Book | N020482 | PRECOSE | Y |
| alogliptin | Orange Book | N022271 | NESINA | Y |
| bexagliflozin | Orange Book | N214373 | BRENZAVVY | Y |
| bromocriptine | Orange Book | N020866 | CYCLOSET | Y |
| bromocriptine | Orange Book | N017962 | PARLODEL | Y |
| canagliflozin | Orange Book | N204042 | INVOKANA | Y |
| colesevelam | Orange Book | N021176 | WELCHOL | Y |
| colesevelam | Orange Book | N022362 | WELCHOL | Y |
| colesevelam | Orange Book | N210895 | WELCHOL | Y |
| dapagliflozin | Orange Book | N202293 | FARXIGA | Y |
| dapagliflozin | Orange Book | N205649 | XIGDUO XR | Y |
| dulaglutide | Purple Book | B125469 | TRULICITY | Y |
| empagliflozin | Orange Book | N206073 | GLYXAMBI | Y |
| empagliflozin | Orange Book | N204629 | JARDIANCE | Y |
| empagliflozin | Orange Book | N206111 | SYNJARDY | Y |
| empagliflozin | Orange Book | N208658 | SYNJARDY XR | Y |
| empagliflozin | Orange Book | N212614 | TRIJARDY XR | Y |
| ertugliflozin | Orange Book | N209803 | STEGLATRO | Y |
| ertugliflozin | Orange Book | N209805 | STEGLUJAN | Y |
| exenatide | Orange Book | N022200 | BYDUREON | Y |
| exenatide | Orange Book | N209210 | BYDUREON BCISE | Y |
| exenatide | Orange Book | N022200 | BYDUREON PEN | Y |
| exenatide | Orange Book | N021773 | BYETTA | Y |
| glimepiride | Orange Book | N020496 | AMARYL | Y |
| glimepiride | Orange Book | N021700 | AVANDARYL | Y |
| glimepiride | Orange Book | N021925 | DUETACT | Y |
| glipizide | Orange Book | N017783 | GLUCOTROL | Y |
| glipizide | Orange Book | N020329 | GLUCOTROL XL | Y |
| glyburide | Orange Book | N017532 | DIABETA | Y |
| glyburide | Orange Book | N021178 | GLUCOVANCE | Y |
| glyburide | Orange Book | N020051 | GLYNASE | Y |
| glyburide | Orange Book | N017498 | MICRONASE | Y |
| insulin aspart | Purple Book | B021172 | NOVOLOG MIX 70/30 | Y |
| insulin aspart | Purple Book | B021172 | NOVOLOG MIX 70/30 FLEXPEN | Y |
| insulin degludec | Purple Book | B203314 | TRESIBA | Y |
| insulin glargine | Purple Book | B021081 | LANTUS | Y |
| insulin glargine | Purple Book | B021081 | LANTUS SOLOSTAR | Y |
| insulin lispro | Purple Book | B205747 | HUMALOG KWIKPEN | Y |
| linagliptin | Orange Book | N201280 | TRADJENTA | Y |
| liraglutide | Orange Book | N206321 | SAXENDA | Y |
| liraglutide | Orange Book | N022341 | VICTOZA | Y |
| metformin | Orange Book | N021410 | AVANDAMET | Y |
| metformin | Orange Book | N021574 | FORTAMET | Y |
| metformin | Orange Book | N020357 | GLUCOPHAGE | Y |
| metformin | Orange Book | N021202 | GLUCOPHAGE XR | Y |
| metformin | Orange Book | N021748 | GLUMETZA | Y |
| metformin | Orange Book | N204353 | INVOKAMET | Y |
| metformin | Orange Book | N205879 | INVOKAMET XR | Y |
| metformin | Orange Book | N022044 | JANUMET | Y |
| metformin | Orange Book | N202270 | JANUMET XR | Y |
| metformin | Orange Book | N201281 | JENTADUETO | Y |
| metformin | Orange Book | N208026 | JENTADUETO XR | Y |
| metformin | Orange Book | N203414 | KAZANO | Y |
| metformin | Orange Book | N021460 | METAGLIP | Y |
| metformin | Orange Book | N021591 | RIOMET | Y |
| metformin | Orange Book | N212595 | RIOMET ER | Y |
| metformin | Orange Book | N209806 | SEGLUROMET | Y |
| metformin | Orange Book | N216743 | ZITUVIMET | Y |
| metformin | Orange Book | N216778 | ZITUVIMET XR | Y |
| miglitol | Orange Book | N020682 | GLYSET | Y |
| nateglinide | Orange Book | N021204 | STARLIX | Y |
| obeticholic acid | Orange Book | N207999 | OCALIVA | Y |
| pioglitazone | Orange Book | N021842 | ACTOPLUS MET | Y |
| pioglitazone | Orange Book | N022024 | ACTOPLUS MET XR | Y |
| pioglitazone | Orange Book | N021073 | ACTOS | Y |
| pioglitazone | Orange Book | N022426 | OSENI | Y |
| pramlintide | Orange Book | N021332 | SYMLIN | Y |
| repaglinide | Orange Book | N022386 | PRANDIMET | Y |
| repaglinide | Orange Book | N020741 | PRANDIN | Y |
| resmetirom | Orange Book | N217785 | REZDIFFRA | Y |
| rosiglitazone | Orange Book | N021071 | AVANDIA | Y |
| saxagliptin | Orange Book | N200678 | KOMBIGLYZE XR | Y |
| saxagliptin | Orange Book | N022350 | ONGLYZA | Y |
| saxagliptin | Orange Book | N209091 | QTERN | Y |
| saxagliptin | Orange Book | N210874 | QTERNMET XR | Y |
| semaglutide | Orange Book | N209637 | OZEMPIC | Y |
| semaglutide | Orange Book | N213051 | RYBELSUS | Y |
| semaglutide | Orange Book | N215256 | WEGOVY | Y |
| semaglutide | Orange Book | N218316 | WEGOVY | Y |
| sitagliptin | Orange Book | N219122 | BRYNOVIN | Y |
| sitagliptin | Orange Book | N021995 | JANUVIA | Y |
| sitagliptin | Orange Book | N202343 | JUVISYNC | Y |
| sitagliptin | Orange Book | N211566 | ZITUVIO | Y |
| sotagliflozin | Orange Book | N216203 | INPEFA | Y |
| tirzepatide | Orange Book | N215866 | MOUNJARO | Y |
| tirzepatide | Orange Book | N215866 | MOUNJARO (AUTOINJECTOR) | Y |
| tirzepatide | Orange Book | N217806 | ZEPBOUND | Y |
| tirzepatide | Orange Book | N217806 | ZEPBOUND (AUTOINJECTOR) | Y |
| cagrilintide | - | - | - | N (Amylin Analogue) |
| danuglipron | - | - | - | N (Oral GLP-1 RA (Small Molecule)) |
| gliclazide | - | - | - | N (Sulfonylharnstoff) |
| insulin icodec | - | - | - | N (Insulin (Weekly)) |
| orforglipron | - | - | - | N (Oral GLP-1 RA (Small Molecule)) |
| pemvidutide | - | - | - | N (GLP-1/Glucagon Dual Agonist) |
| retatrutide | - | - | - | N (GLP-1/GIP/Glucagon Triple Agonist) |
| survodutide | - | - | - | N (GLP-1/Glucagon Dual Agonist) |
| vildagliptin | - | - | - | N (DPP-4 Inhibitor) |

## LOE-Kalender (bis 2036)

| Drug | Trade Name | LOE Date | Jahre bis LOE | Patente | Patent-Typ | Exclusivity |
|------|-----------|----------|---------------|---------|-----------|-------------|
| dulaglutide | TRULICITY | 2026-09-18 | 0.6 | 0 | - | BPCIA-12, BPCIA-4 |
| insulin lispro | HUMALOG KWIKPEN | 2027-05-26 | 1.3 | 0 | - | BPCIA-12, BPCIA-4 |
| insulin degludec | TRESIBA | 2027-09-25 | 1.6 | 0 | - | BPCIA-12, BPCIA-4 |
| glimepiride | AVANDARYL | 2028-06-08 | 2.3 | 2 | Product | - |
| pioglitazone | OSENI | 2029-06-04 | 3.3 | 8 | Substance, Use, Product | - |
| alogliptin | NESINA | 2029-06-16 | 3.3 | 4 | Substance, Use, Product | M-300 |
| canagliflozin | INVOKANA | 2029-08-26 | 3.5 | 8 | Substance, Use, Product | NPP, PED |
| sotagliflozin | INPEFA | 2030-10-07 | 4.7 | 3 | Substance, Use, Product | NCE |
| ertugliflozin | STEGLUJAN | 2030-10-21 | 4.7 | 5 | Substance, Use, Product | - |
| exenatide | BYETTA | 2031-04-04 | 5.1 | 22 | Substance, Use, Product | NPP, PED |
| saxagliptin | QTERNMET XR | 2031-05-12 | 5.3 | 17 | Substance, Use, Product | - |
| bromocriptine | PARLODEL | 2032-04-30 | 6.2 | 13 | Use, Product | - |
| bexagliflozin | BRENZAVVY | 2032-05-14 | 6.3 | 6 | Substance, Use, Product | NCE |

## LOE nach 2036 (starker Patentschutz)

| Drug | Trade Name | LOE Date | Jahre bis LOE | Patente |
|------|-----------|----------|---------------|---------|
| obeticholic acid | OCALIVA | 2036-04-26 | 10.2 | 7 |
| liraglutide | VICTOZA | 2037-07-09 | 11.4 | 4 |
| metformin | AVANDAMET | 2037-12-08 | 11.8 | 43 |
| empagliflozin | SYNJARDY | 2037-12-08 | 11.8 | 44 |
| linagliptin | TRADJENTA | 2037-12-08 | 11.8 | 18 |
| sitagliptin | JUVISYNC | 2040-10-23 | 14.7 | 5 |
| semaglutide | WEGOVY | 2041-02-17 | 15.0 | 24 |
| dapagliflozin | XIGDUO XR | 2041-10-01 | 15.6 | 41 |
| tirzepatide | MOUNJARO (AUTOINJECTOR) | 2041-12-30 | 15.9 | 8 |
| resmetirom | REZDIFFRA | 2045-02-04 | 19.0 | 6 |

## Bereits post-LOE (Generika/Biosimilars moeglich)

| Drug | Trade Name | LOE Date | Jahre seit LOE |
|------|-----------|----------|----------------|
| insulin aspart | NOVOLOG MIX 70/30 FLEXPEN | 2013-11-01 | 12.3 |
| insulin glargine | LANTUS SOLOSTAR | 2012-04-20 | 13.8 |

## Patent-Analyse

- Drugs mit Substance-Patenten: 18
- Drugs mit Use-Patenten: 19
- Drugs mit Product-Patenten: 20
- Durchschnittliche Patente pro Drug (nur Drugs mit Patenten): 14.4

### Patent-Landschaft pro MoA-Klasse

| MoA Class | Avg Patents | Earliest LOE | Latest LOE |
|-----------|------------|-------------|-----------|
| Alpha-Glucosidase-Inhibitor | 0.0 | None | None |
| Amylin Analogue | 0.0 | None | None |
| Bile Acid Sequestrant | 0.0 | None | None |
| Meglitinid | 0.0 | None | None |
| Insulin (Basal) | 0.0 | 2012-04-20 | 2012-04-20 |
| Insulin (Rapid-acting) | 0.0 | 2013-11-01 | 2027-05-26 |
| GLP-1 Receptor Agonist | 12.5 | 2026-09-18 | 2041-02-17 |
| Insulin (Ultra-long-acting) | 0.0 | 2027-09-25 | 2027-09-25 |
| Sulfonylharnstoff | 0.7 | 2028-06-08 | 2028-06-08 |
| Thiazolidinedione (PPAR-gamma) | 4.0 | 2029-06-04 | 2029-06-04 |
| DPP-4 Inhibitor | 11.0 | 2029-06-16 | 2040-10-23 |
| SGLT2 Inhibitor | 20.8 | 2029-08-26 | 2041-10-01 |
| SGLT1/SGLT2 Inhibitor | 3.0 | 2030-10-07 | 2030-10-07 |
| Dopamin-Agonist (D2) | 13.0 | 2032-04-30 | 2032-04-30 |
| FXR Agonist | 7.0 | 2036-04-26 | 2036-04-26 |
| Biguanide | 43.0 | 2037-12-08 | 2037-12-08 |
| GIP/GLP-1 Dual Agonist | 8.0 | 2041-12-30 | 2041-12-30 |
| THR-beta Agonist | 6.0 | 2045-02-04 | 2045-02-04 |

## Probleme & Empfehlungen

### Bekannte Einschraenkungen
- **9 Drugs ohne LOE-Daten:** 7 Pipeline-Drugs (nicht zugelassen), Gliclazide (nicht in USA), Vildagliptin (nur EU)
- **Biologics (Purple Book):** Keine Patent-Daten verfuegbar -- BPCIA 12-Jahres-Exklusivitaet als Proxy verwendet
- **Combo-Products:** Manche Drugs erscheinen in Kombinations-Produkten (z.B. Metformin in Janumet, Invokamet) -- LOE bezieht sich auf das letzte ablaufende Patent aller zugehoerigen Produkte
- **Patent Challenges:** Paragraph IV Challenges und IPR-Entscheidungen nicht beruecksichtigt -- tatsaechliche Generic-Entry kann frueher erfolgen

### Empfehlungen
1. **Dashboard-Integration:** LOE-Kalender als Timeline-Chart, Patent-Portfolio als Bubble-Chart
2. **Commercial Alerts:** Drugs mit LOE < 2 Jahre markieren (Dulaglutide, Insulin Lispro, Insulin Degludec)
3. **BD&L Opportunities:** Post-LOE Drugs als Generika/Biosimilar-Opportunities flaggen
4. **Patent Cliff Analysis:** GLP-1 Klasse hat starken Schutz bis 2037-2041 -- Hochpreisphase
